Yayın:
TRANSPLANTATION FOR RENAL AMYLOIDOSIS

dc.contributor.authorKILICTURGAY, S
dc.contributor.authorHABERAL, M
dc.date.accessioned2026-06-27T12:57:54Z
dc.date.issued1993
dc.description.abstractRenal transplantation therapy performed for amyloid nephropathy is controversial because of the fatal effects of the disease. Amyloidosis is a relatively frequent disease and is generally associated with familial Mediterranean fever (FMF) in Turkey. Renal transplantation in the treatment of amyloid nephropathy started in January 1985. Till now, 18 (3.2%) renal transplantations have been performed on patients who had amyloid nephropathy. The mean follow-up period was 34.6 months. Fourteen renal grafts still function well (creatinine: 1-3.2 mg/dL). The overall 1-year patient and graft survival rates were 88.9% and 83.0%, respectively. These rates are not statistically different from renal transplantations done for other cases of renal failure. Therefore, patients with end-stage renal failure due to amyloidosis can be considered as appropriate candidates for renal transplantation.en
dc.description.urihttps://doi.org/10.3109/08860229309069414
dc.identifier.doi10.3109/08860229309069414
dc.identifier.endpage633
dc.identifier.issn0886-022X
dc.identifier.issue5
dc.identifier.pubmed8290709
dc.identifier.startpage629
dc.identifier.urihttps://hdl.handle.net/20.500.14981/48259
dc.identifier.volume15
dc.identifier.wosA1993MK72600010
dc.language.isoeng
dc.publisherMARCEL DEKKER INC
dc.relation.ispartofRENAL FAILURE
dc.subjectAMYLOIDOSIS
dc.subjectFAMILIAL MEDITERRANEAN FEVER (FMF)
dc.subjectRENAL FAILURE
dc.subjectRENAL TRANSPLANTATION
dc.subjectUrology & Nephrology
dc.titleTRANSPLANTATION FOR RENAL AMYLOIDOSIS
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar